Ardent Health (NYSE:ARDT) Upgraded to Buy at Wall Street Zen

by · The Markets Daily

Wall Street Zen upgraded shares of Ardent Health (NYSE:ARDT – Free Report) from a hold rating to a buy rating in a report issued on Saturday,Wall Street Zen reports.

Other equities research analysts have also recently issued reports about the company. Weiss Ratings upgraded Ardent Health from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, October 6th. BMO Capital Markets assumed coverage on Ardent Health in a research note on Tuesday, September 22nd. They issued a “market perform” rating and a $11.00 price target for the company. Truist Financial upped their price target on Ardent Health from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Stephens increased their price target on Ardent Health from $13.00 to $21.00 and gave the stock an “overweight” rating in a research report on Friday. Finally, Royal Bank Of Canada raised their price objective on Ardent Health from $13.00 to $18.00 and gave the company an “outperform” rating in a report on Friday. Seven research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $13.54.

Check Out Our Latest Analysis on Ardent Health

Ardent Health Trading Up 8.3%

Ardent Health stock opened at $17.23 on Friday. The firm has a market cap of $2.43 billion, a PE ratio of 16.72, a P/E/G ratio of 4.90 and a beta of 0.58. Ardent Health has a 12 month low of $7.71 and a 12 month high of $17.67. The stock’s 50 day simple moving average is $11.44 and its two-hundred day simple moving average is $10.10. The company has a current ratio of 2.10, a quick ratio of 1.99 and a debt-to-equity ratio of 0.61.

Ardent Health (NYSE:ARDT – Get Free Report) last posted its earnings results on Wednesday, November 4th. The company reported $0.31 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.08. Ardent Health had a net margin of 2.27% and a return on equity of 8.49%. The firm had revenue of $1.62 billion during the quarter, compared to analyst estimates of $1.60 billion. Analysts anticipate that Ardent Health will post 1.05 earnings per share for the current year.

Institutional Trading of Ardent Health

Institutional investors have recently modified their holdings of the stock. BlackRock Inc. acquired a new stake in Ardent Health during the 2nd quarter worth $21,415,000. Algert Global LLC grew its holdings in shares of Ardent Health by 1,277.3% during the second quarter. Algert Global LLC now owns 597,745 shares of the company’s stock worth $5,882,000 after buying an additional 554,345 shares in the last quarter. Empowered Funds LLC purchased a new stake in shares of Ardent Health during the second quarter worth $5,425,000. Bank of America Corp DE acquired a new stake in shares of Ardent Health in the second quarter valued at about $3,840,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Ardent Health in the second quarter valued at about $2,377,000.

Key Ardent Health News

Here are the key news stories impacting Ardent Health this week:

  • Positive Sentiment: Ardent reported Q3 earnings of $0.31 per share, ahead of analyst estimates of roughly $0.23–$0.24, and revenue of $1.625 billion versus the $1.60 billion consensus. Recent coverage also highlighted a return to profitability and improved guidance. Zacks Q3 earnings report Profit and guidance coverage
  • Positive Sentiment: Stephens raised its price target to $21 from $13 and maintained an Overweight rating, implying further potential upside from the quoted $17.23 share price. Stephens ratings
  • Positive Sentiment: RBC lifted its target to $18 from $13 and reiterated an Outperform rating, signaling a more positive view after the results. RBC ratings
  • Neutral Sentiment: The strong rally has brought the stock close to its 12-month high, and a recent analysis questioned whether shares may already be above fair value. That could limit further gains if investors have priced in the earnings beat and raised outlook. Valuation analysis
  • Negative Sentiment: Despite beating estimates, quarterly EPS was below the $0.52 reported a year earlier, pointing to year-over-year earnings pressure. Zacks earnings comparison

About Ardent Health

(Get Free Report)

Ardent Health is a U.S. healthcare services company that operates hospitals, outpatient facilities and physician practices. Its services include emergency and acute care, surgery, cardiology, orthopedics, oncology, women’s health, behavioral health, rehabilitation, imaging and other specialty and primary care offerings.

The company serves patients through regional health networks and hospital campuses primarily in Texas, Oklahoma, New Mexico and other U.S. markets. In addition to hospital-based care, Ardent operates outpatient clinics, urgent care locations and other facilities designed to provide services across different stages of the patient-care process.

Ardent Health was founded in 2001 and became a publicly traded company on the New York Stock Exchange in 2024.

Recommended Stories